Mersana Therapeutics - MRSN Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MRSN shares.
View MRSN analyst ratings or view top-rated stocks.

3 equities research analysts have issued 12 month target prices for Mersana Therapeutics' shares. Their MRSN share price forecasts range from $14.00 to $20.00. On average, they anticipate the company's stock price to reach $17.67 in the next twelve months. This suggests a possible upside of 187.3% from the stock's current price.
View analysts price targets for MRSN or view top-rated stocks among Wall Street analysts.

Mersana Therapeutics' stock was trading at $6.22 at the beginning of 2022. Since then, MRSN shares have decreased by 1.1% and is now trading at $6.15.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our MRSN earnings forecast.

Mersana Therapeutics, Inc. (NASDAQ:MRSN) issued its earnings results on Monday, August, 8th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.50) by $0.05. The company earned $4.28 million during the quarter, compared to analyst estimates of $3.18 million. Mersana Therapeutics had a negative net margin of 3,057.88% and a negative trailing twelve-month return on equity of 140.57%.

3 employees have rated Mersana Therapeutics Chief Executive Officer Anna Protopapas on Glassdoor.com. Anna Protopapas has an approval rating of 100% among the company's employees. This puts Anna Protopapas in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Mersana Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Ovid Therapeutics (OVID), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Marvell Technology (MRVL), Inovio Pharmaceuticals (INO), DocuSign (DOCU), Immunomedics (IMMU) and Marinus Pharmaceuticals (MRNS).

(MRSN) raised $75 million in an initial public offering on Wednesday, June 28th 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN."

Mersana Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Bain Capital Life Sciences Investors LLC (8.92%), Millennium Management LLC (4.51%), Woodline Partners LP (3.25%), Candriam S.C.A. (2.05%), Goldman Sachs Group Inc. (1.91%) and State Street Corp (1.67%). Insiders that own company stock include Alejandra Carvajal, Andrew A F Hack, Anna Protopapas, Arvin Yang, Ashish Mandelia, Eva M Jack, Lawrence M Alleva, Lawrence M Alleva, Scott D Sandell, Timothy B Lowinger and Tushar Misra.
View institutional ownership trends.

Shares of MRSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MRSN stock can currently be purchased for approximately $6.15.

Mersana Therapeutics (NASDAQ:MRSN) has a market capitalization of $597.60 million and generates $40,000.00 in revenue each year. The company earns $-170,060,000.00 in net income (profit) each year or ($2.45) on an earnings per share basis.

The company employs 169 workers across the globe.

Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The official website for the company is www.mersana.com. The company can be reached via phone at (617) 498-0020 or via email at ir@mersana.com.